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Abstract
Objective The aim of this meta-analysis was to compare the
efficacy and safety of infliximab-biosimilar and other available
biologicals for the treatment of rheumatoid arthritis (RA),
namely abatacept, adalimumab, certolizumab pegol, etaner-
cept, golimumab, infliximab, rituximab and tocilizumab.
Methods A systematic literature review of MEDLINE
database until August 2013 was carried out to identify
relevant randomized controlled trials (RCTs). Bayesian
mixed treatment comparison method was applied for the
pairwise comparison of treatments. Improvement rates by
the American College of Rheumatology criteria (ACR20
and ACR50) at week 24 were used as efficacy endpoints,
and the occurrence of serious adverse events was consid-
ered to assess the safety of the biologicals.
Results Thirty-six RCTs were included in the meta-analysis.
All the biological agents proved to be superior to placebo. For
ACR20 response, certolizumab pegol showed the highest odds
ratio (OR) compared to placebo, OR 7.69 [95 % CI
3.69–14.26], followed by abatacept OR 3.7 [95 % CI
2.17–6.06], tocilizumab OR 3.69 [95 % CI 1.87–6.62] and
infliximab-biosimilar OR 3.47 [95 % CI 0.85–9.7]. For
ACR50 response, certolizumab pegol showed the highest OR
compared to placebo OR 8.46 [3.74–16.82], followed by toc-
ilizumab OR 5.57 [95 % CI 2.77–10.09], and infliximab-bio-
similar OR 4.06 [95 % CI 1.01–11.54]. Regarding the
occurrence of serious adverse events, the results show no sta-
tistically significant difference between infliximab-biosimilar
and placebo, OR 1.87 [95 % CI 0.74–3.84]. No significant
difference regarding efficacy and safety was found between
infliximab-biosimilar and the other biological treatments.
Conclusion This is the first indirect meta-analysis in RA that
compares the efficacy and safety of biosimilar-infliximab to
the other biologicals indicated in RA. We found no significant
difference between infliximab-biosimilar and other biological
agents in terms of clinical efficacy and safety.
Keywords Arthritis  Rheumatoid  Biosimilar
pharmaceuticals  Meta-analysis  Mixed treatment
comparison
JEL Classification I10  I19
Introduction
Currently eight biological medicines—namely, abatacept,
adalimumab, certolizumab pegol, etanercept, golimumab,
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infliximab, rituximab and tocilizumab—are registered by
the European Medicines Agency (EMA) for the treatment
of rheumatoid arthritis (RA). These biologicals are indi-
cated for the treatment of adult patients with active disease
when ‘‘the response to disease-modifying antirheumatic
drugs (DMARDs), including methotrexate (MTX), has
been inadequate.’’ Adalimumab, etanercept, golimumab,
infliximab are also indicated for ‘‘adult patients with
severe, active and progressive disease not previously
treated with MTX or other DMARDs’’ as a ‘first-line
therapy’.1,2
In September 2013, infliximab-biosimilar therapy (CT-
P13, Trade names: Remsima and Inflectra) was also
licensed in the EU for the treatment of RA. According to
the EMA, Remsima and Inflectra are ‘biosimilar’3 medi-
cines of infliximab.
The results of the randomized controlled trial (RCT)
with biosimilar-infliximab treatment in RA were published
in May 2013 [1]. PLANETRA was a double-blind, non-
inferiority study, and aimed to prove the similar efficacy
and safety of infliximab-biosimilar in combination with
MTX and the originator infliximab combined with MTX.
The primary endpoint of the trial was the therapeutic
equivalence of clinical response according to ACR20 cri-
teria at week 30 (See the definition of ACR20 in the
‘‘Methods’’ section). The study was performed between
November 2010 and November 2011 at 100 centers across
19 countries in Europe, Asia, Latin America and the
Middle East. Altogether, 606 patients with active RA
despite MTX treatment were enrolled in the study.
According to the results, at week 30, ACR20 and ACR50
responses were 60.9 and 35.1 %, respectively, on the inf-
liximab-biosimilar arm, and 58.6 and 34.2 % on the orig-
inator infliximab arm in the intention-to-treat population.
The difference not statistically significant at these two
efficacy endpoints. Nor was a significant difference found
in other efficacy and safety endpoints.
The aim of this study is to compare the efficacy and
safety of the new infliximab-biosimilar treatment to the
available originator biological drugs. We carry out sys-
tematic literature review and meta-analysis of published
RCTs with infliximab-biosimilar and other biological
treatments in the recommended doses defined by EMA’s
product characteristic information in RA, applying mixed
treatment comparison (MTC). This method allows us to
carry out pairwise comparison of treatments with different
comparators. In our case, infliximab-biosimilar is only
compared to the originator infliximab, while other biolog-
icals are compared to placebo in most of the studies.
According to our knowledge, no indirect meta-analyses
have yet been published that involve the infliximab-bio-
similar treatment in the comparison.
Methods
Treatments
The analysis compared the recommended doses of bio-
logical DMARDs indicated in RA:4 abatacept (10 mg/kg at
days at weeks 0, 2 and 4, and every 4 weeks thereafter, or
by patient groups based on patient weight\60 kg, 500 mg;
60–100 kg, 750 mg;[100 kg, 1,000 mg, administered as a
30-min intravenous infusion); adalimumab (40 mg every
other week as subcutaneous injection); certolizumab pegol
(400 mg at 0, 2, 4 weeks and then 200 mg at every
2 weeks or 400 mg at every 4 weeks as subcutaneous
injection); etanercept (25 mg twice weekly or 50 mg once
weekly as subcutaneous injection); golimumab (50 mg
once a month as subcutaneous injection); infliximab (3 mg/
kg at 0, 2, 6 weeks and then every 8 weeks as intravenous
infusions over a 2-h period) rituximab (1,000 mg on weeks
0, 2 as intravenous infusions); tocilizumab (8 mg/kg every
4 weeks as intravenous infusions) and infliximab-biosimi-
lar (CT-P13) (3 mg/kg at 0, 2, 6 weeks and then every
8 weeks as intravenous infusions over a 2-h period).
In RA, infliximab-biosimilar (as well as the originator
infliximab) must be administered concomitantly with
MTX. Thus, we only included studies evaluating combi-
nation therapy with biologicals and conventional synthetic
DMARD (csDMARD)5 In this way, we expected to
increase the comparability of the results.
Endpoints
The rates of patients who achieved ACR20 and ACR50
response at week 24 were used as efficacy endpoints in the
meta-analysis of RA trials. The American College of
Rheumatology (ACR) response core set consists of a tender
1 The product information details can be found at http://www.ema.
europa.eu/ema/.
2 Also when the patient is intolerant to previous therapy with tumour-
necrosis-factor (TNF) antagonists.
3 According to the definition of EMA, ‘‘A biosimilar medicine is a
medicine which is similar to a biological medicine that has already
been authorized (the ‘biological reference medicine’). The active
substance of a biosimilar medicine is similar to that of the biological
reference medicine. Biosimilar and biological reference medicines are
used in general at the same dose to treat the same disease.’’
4 Anakinra is also registered for the treatment of RA by the EMA;
however, its utilization has not spread in the clinical practice of CEE
countries where infliximab-biosimilar is marketed. Thus, anakinra
was not included in the meta-analysis.
5 Adalimuab, certolizumab, etanercept and tocilizumab can be
administered as monotherapy, in the case of intolerance to
methotrexate.
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joint count, swollen joint count, patient’s assessment of
pain, patient’s and physician’s global assessments of dis-
ease activity, patient’s assessment of physical function
(HAQ), and laboratory evaluation of one acute-phase
reactant [2]. ACR criteria are indicated as ACR20, ACR50,
and ACR70, reflecting 20, 50, or 70 % relative improve-
ment compared to baseline. Most of the RA clinical trials
with biologicals use ACR20 as primary endpoint, but also
report the percentage of study participants who achieve
ACR50 response as a secondary endpoint.
The safety of biological therapies was also evaluated.
The occurrence of serious adverse events at week 24 of the
treatment was used as safety endpoint in the analysis.
Search strategy
Electronic databases (MEDLINE and Cochrane Library) as
well as references of retrieved articles were searched. The
Cochrane Highly Sensitive Search Strategy [3] was applied
to identify randomized controlled publications and was
combined with the disease MeSH terms ‘arthritis, rheu-
matoid’ and the drug names.6
The search dates were 1 November 2009 to 20 August
2013. References of RCTs from earlier time periods were
taken from our previous systematic review [4].
A separate search was carried out to identify RCTs with
a biosimilar agent with the generic name (CT-P13), without
any restrictions.
Exclusion and inclusion criteria
We have applied the following inclusion criteria:
• Double-blind, parallel RCTs with full paper obtainable
(studies with only abstracts available were excluded).
Non-randomized or uncontrolled studies, observational
studies, case series, letters to the editor, studies with no
abstracts or with conference abstracts only were not
included.
• The patients of interest are adults with moderate-to-
severe RA. (Trials in diseases other than RA were not
included.)
• Head-to-head trials of combined biological therapies or
studies with MTX or other csDMARD therapy control.
• RA patients in at least one arm of the trial must receive one
of the following treatments: abatacept, adalimumab,
certolizumab pegol, etanercept, golimumab, infliximab,
rituximab, tocilizumab or infliximab-biosimilar treatment
in the licensed dose combined with csDMARDs.
We have applied the following exclusion criteria:
• Off-label doses.
• Monotherapy in RA (infliximab-biosimilar can be
administered only in combination with MTX; therefore,
only combination therapies were compared).
• Studies reporting solely on laboratory measures aimed
at investigating disease, or treatment mechanisms and
which do not report relevant clinical outcomes.
• Studies involving patients with age \18 years.
• Pilot studies.
• Studies shorter than 20 weeks, or studies that do not
report ACR50 response at month 6.
• Studies where all the patients enrolled previously failed
biological therapy.
RA trials range widely in design regarding patient
population. Some of them include patients not responding
to csDMARD therapy, while others involve csDMARD-
naı¨ve patients. The authorization of infliximab-biosimilar
also allows the application of the drug for RA patients
previously not treated with MTX or other csDMARDs, in
the case of severe, active and progressive disease. Thus, we
included studies with MTX-naı¨ve (or csDMARD-naı¨ve)
patients in the analysis as well.
However, we excluded studies that only involved
patients who failed previous biological therapy.
Data extraction and quality assessment
Data were extracted by two independent researchers and
checked by a third reviewer. Any disagreement was
resolved through discussion until consensus was reached.
For each selected study, details regarding study design,
patients’ demographic and morbidity characteristics,
treatment interventions, end-points and duration of follow-
up were subtracted.
The quality of selected studies was evaluated using the Ja-
dad score [5]. This is the most frequently used scale in quality
assessment of clinical trials [6]. The Jadad scale assesses the
quality of published clinical trials through methods of random
assignment, double blinding, and the withdrawals and dropout
of patients. Jadad score ranges from zero to five.
Meta-analysis: mixed treatment comparison
We have conducted a meta-analysis to compare the effi-
cacy and safety of the biologicals included in the studies.
An indirect comparison of study outcomes for biological
therapies was carried out. In this paper, we examine the
6 (arthritis. rheumatoid‘‘[MeSH Terms]) AND (abatacept OR ada-
limumab OR certolizumab pegol OR golimumab OR infliximab OR
etanercept OR rituximab OR tocilizumab) AND ((randomized
controlled trial[pt] OR controlled clinical trial[pt] OR random-
ized[tiab] OR placebo[tiab] OR ’’clinical trials as topic‘‘[MeSH
Terms:noexp] OR randomly[tiab] OR trial[ti]) NOT (’’ani-
mals‘‘[MeSH Terms] NOT ’’humans‘‘[MeSH Terms])) AND
(’’2009/11/01‘‘[PDAT]: ’’2013/08/20‘‘[PDAT]).
A mixed treatment comparison
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relative effectiveness of each individual treatment using the
Lu method for combining direct and indirect evidence in
mixed treatment comparisons (MTC), a Bayesian approach
[7, 8]. Statistical models developed by NICE Decision
Support Unit (DSU) were used. We estimated the posterior
densities for all unknown parameters using MCMC (Mar-
kov chain Monte Carlo) for each model in WinBUGS
version 1.4.3 (MRC Biostatistics Unit, Cambridge, UK).
Each outcome measure was analyzed using random effects
models.
All MTC models used the odds ratio (OR) as the mea-
sure of relative treatment effect, and assumed that treat-
ment effects on the odds-ratio scale were multiplicative and
exchangeable between trials. We also present the 95 %
credibility intervals (CI) containing the true value of OR
with 95 % probability.
Results
Literature review
The search in MEDLINE yielded 354 potential citations for
RCTs examining the biological treatment of RA (search
period: 01.11.2009–20.08.2013). In RA, 15 RCTs identi-
fied by our search met our inclusion criteria. Furthermore,
out of 32 RCTs identified by Brodszky et al. [4], 21 were
taken and included in our analysis. The rest were not
included because they were either monotherapy studies, or
examined biologicals after previous failure with biologicals
[9–12].
The search for infliximab-biosimilar did not identify
RCTs other than the PLANETRA trial [1].
Altogether, we included 36 RCTs (RA patients with
combination therapy of MTX or other DMARDs). Most of
the studies compared biologicals with placebo: five abata-
cept [13–17], seven adalimumab [18–24], three certo-
lizumab pegol [25–27], four etanercept [28–31],7 four
golimumab [32–35], three infliximab [36–38], four ritux-
imab [39–42] and three tocilizumab [43–45]. One study
compared abatacept versus adalimumab [46], one inflix-
imab versus abatacept versus placebo [47] and one inflix-
imab versus infliximab-biosimilar [1]. The number of trials
in given comparisons might be different (e.g., on efficacy
or safety endpoints) because of the specific inclusion
criteria for each comparison and the distinct endpoints
reporting across trials.
The main characteristics of the trials, i.e., number of
patients, treatment arms, and JADAD score, are presented
in Table 1.
Out of the 36 RA trials included in this analysis, eight
studies applied study drugs to MTX-naı¨ve patients [16, 21,
24, 30, 31, 33, 37, 42], and one study on csDMARD-naı¨ve
patients [23]. The rest of the studies involved patients with
prior inadequate response to csDMARDs.
In some abatacept, rituximab, tocilizumab and goli-
mumab studies [13, 15, 34, 40, 45], patients were not
excluded if previously treated with biologicals prior to
the study. Since the share of patients who were treated
with biologicals before was relatively low in these
studies, we included them in the meta-analysis. However,
studies where all patients were previously treated with
biologicals [12] or all patients gave prior inadequate
response to biologicals [9–11] were not included in our
meta-analysis.
Most of the RCTs reported ACR20 and ACR50 response
at week 24. In contrast, the infliximab-biosimilar RCT
reported results at week 30. However, patients in the inf-
liximab-biosimilar study received the same number of
infusions as patients in the infliximab trials.
Mixed treatment comparison: efficacy and safety
Efficacy
Out of the 36 RA trials identified by our search, 34 reported
results for ACR20 response at week 24, and 35 reported
ACR50 response at week 24. Weinblatt et al. [15] reported
study results only on safety and Westhovens et al. [16] did
not report ACR20 response. Data for 15,044 patients for
ACR20 response and 14,535 for ACR50 response were
included in the analysis.
All biological drugs were found to be superior to pla-
cebo regarding ACR20 and ACR50 responses. The results
are presented in Table 2. On the ACR20 endpoint, certo-
lizumab pegol showed the highest odds ratio compared to
placebo, OR 7.69 [95 % CI 3.69–14.26], followed by
abatacept OR 3.7 [95 % CI 2.17–6.06], tocilizumab OR
3.69 [1.87–6.62], and infliximab-biosimilar OR 3.47 [95 %
CI 0.85–9.7].
For ACR50 response, certolizumab pegol showed the
highest OR compared to placebo OR 8.46 [3.74–16.82],
followed by tocilizumab OR 5.57 [95 % CI 2.77–10.09],
and infliximab-biosimilar OR 4.06 [95 % CI 1.01–11.54].
The results of pairwise comparison did not show sig-
nificant differences between the efficacy of infliximab-
biosimilar and the other biologicals in terms of ACR20 or
ACR50 response at week 24 (see Fig. 1).
7 Moreland et al. [31] was a 2-year, randomized, double-blind trial
with four treatment arms: immediate treatment with MTX plus
etanercept, immediate oral triple therapy (MTX plus sulfasalazine
plus hydroxychloroquine), or step-up from MTX monotherapy to one
of the combination therapies (MTX plus etanercept or MTX plus
sulfasalazine plus hydroxychloroquine) at week 24. Since before
week 24, treatment arms with MTX ? etanercept and MTX alone
were selected to be included in this meta-analysis.
P. Baji et al.
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Table 1 Characteristics of the RCTs in RA included in the analysis
Study Treatment arms Study
duration
(weeks)
N
(ITT)
Age,
years
HAQ
score
Disease
duration,
years
JADAD
score
Kremer [13] ABT(2 mg/kg) ? MTX 26 105 54.4 1 9.7 5
ABT(10 mg/kg) 1 MTX 115 55.8 1 9.7
Placebo 1 MTX 119 54.7 1 8.9
Kremer [14] ABT(10 mg/kg) 1 MTX 26 433 51.5 1.7 8.5 5
AIM Placebo 1 MTX 219 50.4 1.7 8.9
Weinblatt [15] ABT(10 mg/kg) 1 DMARD 52 959 52.5 1.5 10.4 5
ASSURE Placebo 1 DMARD 482 52.1 1.6 10.4
Westhovens [16]* ABT(10 mg/kg) 1 MTX 104 256 NR 1.7 0.56 5
Placebo 1 MTX 253 1.7 0.56
Takeutchi [17] ABA(10 mg/kg) 1 MTX 61 53.4 1.33 7.4 5
ABA(2 mg/kg) ? MTX 67 52.5 1.24 8.5
Placebo 1 MTX 66 53.4 1.5 7.3
Furst [18] ADL(40 mg/eow) 1 DMARD 24 318 55 1.4 9.3 3
STAR Placebo 1 DMARD 318 55.8 1.4 11.5
Keystone [19] ADL(20 mg/ew) ? MTX 24 212 57.3 1.4 11 3
ADL(40 mg/eow) 1 MTX 207 56.1 1.5 11
Placebo 1 MTX 200 56.1 1.5 10.9
Weinblatt [20]
ARMADA
ADL(20 mg/eow) ?MTX 24 69 53.5 1.52 13.1 3
ADL(40 mg/eow) 1 MTX 67 57.2 1.55 12.2
ADL(80 mg/eow) ? MTX 73 55.5 1.55 12.8
Placebo 1 MTX 62 56 1.64 11.1
Breedveld [21]
PREMIER*
ADL(40 mg/eow) 52 274 52.1 0.7 1.6 5
ADL(40 mg/eow) 1 MTX 268 51.9 0.7 1.5
Placebo 1 MTX 257 52 0.7 1.5
Kim [22] ADL(40 mg/eow) 1 MTX 24 65 48.5 1.4 6.8 1
Placebo 1 MTX 63 49.8 1.3 6.9
Detert [23]
HIT HARD*
ADL(40 mg/eow) 1 MTX 24 87 47.2 1.4 1.8 5
Placebo 1 MTX 85 52.5 1.3 1.6
Kavanaugh [24] ADL(40 mg/eow) 1 MTX 26 515 50.7 1.61 0.3 4
OPTIMA* Placebo 1 MTX 517 50.4 1.6 0.4
Keystone [25]
RAPID1
CRT(200 mg) 1 MTX 52 393 51.4 1.7 6.1 5
CRT(400 mg) ? MTX 390 52.4 1.7 6.2
Placebo 1 MTX 199 52.2 1.7 6.2
Smolen [26]
RAPID2
CRT(200 mg) 1 MTX 24 246 51.9 1.6 6.1 3
CRT(400 mg) ? MTX 246 52.2 1.6 6.5
Placebo 1 MTX 127 51.5 1.6 5.6
Choy [27] CRT(400meg/4 week) 1 MTX 24 126 53 1.4 9.4 5
Placebo 1 MTX 121 55.6 1.5 9.9
Weinblatt [28] ETN(2 3 25 mg/ew) 1 MTX
Placebo 1 MTX
24 59 48 1.5 13 3
30 53 1.5 13
Emery [30]
COMET*
ETN(50 mg/ew) 1 MTX
Placebo 1 MTX
52 274 50.5 1.7 0.7 5
268 52.3 1.6 0.8
Klareskog [29]
TEMPO
ETN(2 3 25 mg/ew) 24 223 53.2 1.7 6.3 5
ETN(2 3 25 mg/ew) 1 MTX 231 52.5 1.8 6.8
Placebo 1 MTX 228 53 1.7 6.8
Moreland [31] (till week
24)*
ETN(50 mg/ew) 1 MTX 102 244 50.7 NR 3.5 5
Placebo 1 MTX 379 48.8 3.4
A mixed treatment comparison
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Table 1 continued
Study Treatment arms Study
duration
(weeks)
N
(ITT)
Age,
years
HAQ
score
Disease
duration,
years
JADAD
score
Keystone [32]
GO-FORWARD
GOL(100 mg) ? placebo 24 133 51 1.4 5.9 5
GOL(50 mg) 1 MTX 89 52 1.4 4.5
GOL(100 mg) ? MTX 89 50 1.4 6.7
Placebo 1 MTX 133 52 1.3 6.5
Emery [33]* GOL(100 mg) ? PLACEBO 24 159 48.2 1.6 4.1 5
GOL(50 mg) 1 MTX 159 50.9 1.5 3.5
GOL(100 mg) ? MTX 159 50.2 1.5 3.6
Placebo 1 MTX 160 48.6 1.5 2.9
Kremer [34] GOL(50 mg) 24 128 NR 1.6 7.4 5
GOL(50 mg) 1 MTX 129 1.5 8.1
GOL(100 mg) 129 1.5 8.4
GOL(100 mg) ? MTX 128 1.5 9.4
Placebo 1 MTX 129 1.5 7.4
Tanaka [35] GOL(50 mg) 1 MTX 86 50.4 1 8.8 5
GOL(100 mg) ? MTX 87 50 0.9 8.1
Placebo 1 MTX 88 51.1 1 8.7
Maini [36] INF(3 mg/kg/4 weeks) 1 MTX 30 86 56 1.8 8.4 5
ATTRACT INF(3 mg/kg/4 weeks) ? MTX 86 51 1.8 7.2
INF(10 mg/kg/8 weeks) ? MTX 81 55 1.8 9
INF(10 mg/kg/4 weeks) ? MTX 81 52 1.5 8.7
Placebo 1 MTX 88 51 1.8 8.9
Clair [37]
ASPIRE*
INF(3 mg/kg) 1 MTX 54 373 51 1.5 0.8 3
INF(6 mg/kg) ? MTX 378 50 1.5 0.9
Placebo 1 MTX 298 50 1.5 0.9
Westhovens [38]
START
INF(3 mg/kg) 1 MTX 22 361 53 1.5 7.8 5
INF(10 mg/kg) ? MTX 360 52 1.5 6.3
Placebo 1 MTX 363 52 1.5 8.4
Edwards [39] RTX(2 3 500 mg) 24 40 54 1.8 12 3
RTX(2 3 500 mg) ? cyclo. 41 53 9
RTX(2 3 500 mg) 1 MTX 40 54 10
Placebo 1 MTX 40 54 11
Emery [40]
DANCER
RTX(2 3 500 mg) 1 MTX 24 123 51.4 1.7 11.1 5
RTX(2 3 1,000 mg) ? MTX 122 51.1 1.8 10.8
Placebo 1 MTX 123 51.1 1.7 9.3
Emery [41]
SERRENE
RTX(2 3 500 mg) 1 MTX 168 NR NR 7.1 3
RTX(2 3 1,000 mg) ? MTX 172 6.61
Placebo 1 MTX 172 7.48
Tak [42]
IMAGE*
RTX(2 3 500 mg) 1 MTX 249 NR NR 0.99 5
RTX(2 3 1,000 mg) ? MTX 250 0.92
Placebo 1 MTX 249 0.91
Smolen [43]
OPTION
TCL(8 mg/kg) 1 MTX 24 205 50.8 1.6 7.5 5
TCL(4 mg/kg) ?MTX 214 51.4 1.6 7.4
Placebo 1 MTX 204 50.6 1.5 7.8
Genovese [44]
TOWARD
TCL(8 mg/kg) 1 DMARD 24 805 53 1.5 9.8 5
Placebo 1 DMARD 415 54 1.5 9.8
Yazici [45] TCL(8 mg/kg) 1 DMARD 409 55.2 NA 8.62 3
ROSE Placebo 1 DMARD 207 55.8 NA 8.52
P. Baji et al.
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Safety and tolerability
Thirty studies reported the occurrence of serious adverse
events at week 24. Data for 14,708 patients were included
in the analysis.
Etanercept had the lowest OR 0.84 [95 % CI 0.48–1.34],
followed by adalimumab OR 0.85 [95 % CI 0.57–1.19] and
abatacept 0.91 [95 % CI 0.64–1.18]. For infliximab-biosimi-
lar the OR was 1.87 [95 % CI 0.74–3.84], while for the
originator infliximab the OR was 1.15 [0.77–1.64]. In this
endpoint, the lower ORs are in favor of biologicals, as the
lower OR, the lower the chance of the occurrence of serious
adverse events (AEs) compared to placebo. Certoluzimab
pegol was found to have significantly worse safety profile than
placebo OR 2.02 [1.16–3.3]. For the rest of the treatments, the
difference between placebo and biological treatments was not
significant.
Regarding the pairwise comparison of the treatments,
we found no significant difference in the safety of inflix-
imab-biosimilar and other biological treatments (see
Fig. 2).
Discussion
The efficacy and safety of infliximab-biosimilar was
compared only to infliximab in a non-inferiority RCT. This
study was aimed to carry out an indirect meta-analysis and
compare the efficacy and safety of infliximab-biosimilar to
each biological available for the treatment of RA. We used
mixed-treatment comparison, which in contrast to tradi-
tional methods allows the pairwise comparison of the
treatments with different comparators. This was necessary,
as infliximab-biosimilar was only compared to the origi-
nator infliximab treatment, while the other biologicals were
usually compared to placebo, and moreover, head-to-head
comparisons were rare.
Our study, involving altogether 15,044 RA patients, has
demonstrated that there is no significant difference in the
efficacy and safety of infliximab-biosimilar and other bio-
logical drugs in RA.
Thus far, several reviews have been published synthe-
sizing the findings on direct comparisons of a single bio-
logical agent combined with sDMARDs and sDMARDs
Table 1 continued
Study Treatment arms Study
duration
(weeks)
N
(ITT)
Age,
years
HAQ
score
Disease
duration,
years
JADAD
score
Weinblatt [46] ABT(10 mg/kg) 1 MTX 318 51.4 1.5 1.9 5
ADL 1 MTX 328 51 1.5 1.7
Schiff [47]
ATTEST
ABT(10 mg/kg) 1 MTX 52 156 49 1.8 7.9 5
INF (3 mg/kg) 1 MTX 165 49.1 1.7 7.3
Placebo 1 MTX 110 49.4 1.8 8.4
Yoo [1] INF-biosimilar(3 mg) 1 MTX 30 304 50 1.6 NR
PLANETRA INF(3 mg) 1 MTX 302 50 1.6
ABT abatacept, ADA adalimumab, CRT certolizumab pegol, ETN etanercept, GOL golimumab, INF infliximab, RTX rituximab, TCL tocilizumab.
Bold letters indicate the treatment arms included in the meta-analysis. * Studies with MTX-naı¨ve or csDMARD-naı¨ve patients
Table 2 The efficacy and safety of biological and biosimilar treatment of RA compared to placebo, the results of the mixed treatment
comparison
Treatment ACR20 at week 24
OR [95 % CI]
ACR50 at week 24
OR [95 % CI]
Serious AEs
OR [95 % CI]
Abatacept vs placebo 3.7 [2.17–6.06] 3.64 [2.25–5.76] 0.91 [0.64–1.18]
Adalimumab vs placebo 2.92 [1.9–4.36] 3.48 [2.27–5.22] 0.85 [0.57–1.19]
Certolizumab pegol vs placebo 7.69 [3.69–14.26] 8.46 [3.74–16.82] 2.02 [1.16–3.3]
Etanercept vs placebo 2.72 [1.47–4.71] 3.07 [1.68–5.38] 0.84 [0.48–1.34]
Golimumab vs placebo 2.8 [1.5–4.83] 2.83 [1.48–4.98] 1.63 [0.74–3.14]
Infliximab vs placebo 2.71 [1.51–4.54] 3.3 [1.82–5.66] 1.15 [0.77–1.64]
Rituximab vs placebo 2.81 [1.5–4.86] 3.19 [1.66–5.62] 1.18 [0.7–1.87]
Tocilizumab vs placebo 3.69 [1.87–6.62] 5.57 [2.77–10.09] 1.46 [0.89–2.27]
Infliximab-biosimilar vs placebo 3.47 [0.85–9.7] 4.06 [1.01–11.54] 1.87 [0.74–3.84]
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alone [48–57]. These studies come to the same conclusion
as ours, that biologicals (including the originator inflix-
imab) are significantly more efficient treatments compared
to csDMARDs. Only the latest by Nam et al. [48] involved
infliximab-biosimilar in the review; however, its efficacy
and safety was not compared to other biologicals [48].
Fig. 1 Efficacy results of the mixed treatment comparison of
infliximab-biosimilar versus other biologicals in RA–ACR20 and
ACR50 response at week 24. The infliximab-biosimilar study
presented results for week 30. The figure presents odds ratios (OR)
between treatments. If the point estimate is greater than 1, then the
biosimilar treatment is more effective (although not necessarily
statistically significantly more effective) compared to the originator
biologicals. Credibility intervals provide information on whether the
difference between treatments is statistically significant. If the CI
contains the value 1, the difference is not statistically significant
Fig. 2 Safety: Serious adverse events (AEs) in RA infliximab-
biosimilar versus other biologicals at week 24. The infliximab-
biosimilar study presented results for week 30. The figure presents
odds ratios (OR) between treatments. If the point estimate is lower
than 1, then the biosimilar treatment is safer (although not necessarily
statistically significantly safer). Credibility intervals provide infor-
mation on whether the difference between treatments is statistically
significant. If the CI contains the value 1, the difference is not
statistically significant
P. Baji et al.
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Indirect comparisons published previously have not
considered infliximab-biosimilar, but the originator
infliximab.
Some studies that carried out indirect comparison of the
efficacy of different biologicals in RA found that the dif-
ference between infliximab and other biologicals were not
statistically significant [4, 58–61], which supports our
results for infliximab and infliximab-biosimilar.
However, some studies found significant differences
between infliximab and certolizumab pegol in favor of
certolizumab pegol [62–64]. Schmitz et al.’s study [63]
involving 16 RCTs with patients who produced an inade-
quate response to MTX, and Turkstra et al.’s study [64]
involving 27 RCTs with patients who produced an inade-
quate response to MTX found certolizumab pegol to be
superior to infliximab in ACR20 and ACR50 responses at
month 6. In our study, we also found that certolizumab
pegol gave the highest ORs in terms of ACR20 and ACR50
response, but the difference between cetrolizumab pegol
and infliximab and infliximab-biosimilar therapies were not
statistically significant. In contrast to our study, the meta-
analyses of Turkstra et al. [64] and Schmitz et al. [63] did
not include the results of a recently published RCT with
certolizumab pegol [27]. Furthermore, they also involved
studies where patients were enrolled after MTX or other
csDMARD failure, and studies where biologicals were
administered in monotherapy. Turkstra et al. [64] included
only two RCTs for infliximab (one small and one large),
while we included five. These differences might partly
explain the contradictory results.
Nevertheless, the outstanding result of certolizumab
pegol deserves further considerations. In two of the certo-
lizumab pegol RCTs (RAPID 1 and RAPID 2), patients
who did not show an ACR20 response at both weeks 12
and 14 were to be withdrawn from the study [25, 26]. This
design differs from the first biological RCTs in RA, and the
early evaluation of efficacy reflects the EMA guideline
(2003), which suggests to consider the principle as follows:
‘‘since it would be unethical to retain a patient with rheu-
matoid arthritis on placebo treatment indefinitely, the
duration of placebo control must necessarily be limited.
Depending on the severity and the activity of the disease,
3–6 months is acceptable’’ [65]. As a consequence, we
observe an extremely high rate of early withdrawal in the
placebo group in these certolizumab pegol trials [66]. The
high withdrawal rates resulted in the high OR rate of cer-
tolizumab pegol compared to placebo.
Launois et al. [66] also doubt the comparability of the
certolizumab pegol studies, due to the low ACR responses
to placebo mentioned as a limitation in their study. How-
ever, they do not discuss that the low placebo response rate
(as well as high ORs) and the extremely high rate of early
withdrawal in the placebo group are in correlation.
Regarding safety and tolerability, some of the studies
found significant differences between treatments, e.g., in
favor of etanercept [58] or in favor of abatacept compared
to a combined group of biologicals [61]. However, these
studies examined a tolerability endpoint, namely the
withdrawal of therapy due to adverse events, while we
examined safety in terms of the occurrence of serious
adverse events. The unfavorable safety results for certo-
lizumab pegol can be also explained by the different study
design and the extremely high withdrawal rates in the
placebo group (see above).
We have to acknowledge some limitations of our study.
Due to the diversity of study designs regarding patient
population, we pooled the evidence from studies with
DMARD-naı¨ve patients (i.e., early aggressive treatment)
and patients with inadequate response to DMARDs. Yet,
Brodszky et al. [4] found a significant positive association
with the disease duration efficacy of the drug. Our reasons
to pool evidence from studies with different study popu-
lations were twofold: (1) some of the biologicals are also
indicated for patients not previously treated with MTX or
other csDMARDs, in the case of severe, active and pro-
gressive disease; (2) excluding studies with DMARD-naı¨ve
patients would have resulted in the exclusion of studies
with high number of patients, which would result in biased
results. For example, three of the four etanercept studies
involved DMARD-naı¨ve patients (N = 1,624), while only
one with low sample population studied the efficacy of
etanercept on patients who did not respond to previous
treatments with csDMARD (N = 89).
Also, only combination therapy with csDMARDs was
examined in this study. Furthermore, it is to be highlighted
that the infliximab-biosimilar study reports efficacy and
safety results at week 30, 6 weeks later than most of the
studies included in the analysis, which report the results at
week 24. However, patients in the infliximab-biosimilar
study received the same number of injections as patients in
the infliximab studies.
We acknowledge that estimated ORs might vary
depending on the designs of the mixed treatment comparison
(e.g., whether monotherapy studies, or studies with
DMARD-naı¨ve patients, are included); however, we found
that the main conclusions, i.e., the similar efficacy and safety
of biologicals, did not change. Also, the analysis was limited
to the endpoints selected; however, the examination of other
safety and efficacy endpoints may be of interest as well.
To conclude, according to our knowledge, this is the first
study in RA that includes infliximab-biosimilar in a meta-
analysis, and compares it to the originator biologicals that
are approved for use in European clinical practice. Our
study, involving data for 15,044 RA patients, has demon-
strated the similar efficacy and safety profile of infliximab-
biosimilar treatment compared to other biologicals. The
A mixed treatment comparison
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results might support clinical as well as financial decision
making, providing evidence on the similar efficacy and
safety of infliximab-biosimilar and other biologicals indi-
cated in RA.
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